Risk of Hydroceles Following Pyeloplasty

This population-based study will use provincial health administrative data to examine the risk of hospital admission for hydrocelectomy among males who underwent laparoscopic pyeloplasty, compared with males from the general population with similar baseline health characteristics. We will use health administrative data from Ontario, Canada, to identify males who had a laparoscopic pyeloplasty between 1992 and 2024. We will calculate a propensity score based on sociodemographic characteristics, comorbidities, and health care utilization. We will then match laparoscopic pyeloplasty males to non-pyeloplasty male controls (1:4) based on propensity score, age, and index date. The primary outcome is hospital admission for hydrocelectomy. The secondary outcomes are a hydrocele diagnosis and receipt of a scrotal ultrasound.

Study Overview

• Status: Completed
• Conditions: Pyeloplasty; Hydrocele; Hydrocelectomy
• Intervention / Treatment: Procedure: Pyeloplasty

Detailed Description

*Background*

Previous reports among male living kidney donors have documented postoperative testicular pain and/or scrotal swelling on the side of nephrectomy. Many affected donors were subsequently diagnosed with hydroceles and required surgical intervention (hydrocelectomy). However, existing studies were generally small, had limited follow-up, and lacked appropriate comparison groups.

To address these limitations, a large population-based study of living kidney donors was conducted. Male donors had a substantially higher incidence of scrotal surgery than matched nondonors: 7.8% of donors (70/898) underwent scrotal surgery compared with 0.2% of nondonors (19/8,980), corresponding to 8.3 versus 0.2 events per 1,000 person-years. The hazard ratio was 38.8 (95% CI, 22.1-67.9; P < 0.001), and the 20-year cumulative incidence was 13.8% in donors versus 0.7% in nondonors.

In an exploratory secondary analysis, additional surgical cohorts were examined, and similar signals were observed among non-donors undergoing other kidney surgeries. For example, among patients who underwent pyeloplasty, the incidence of scrotal surgery was 1.8 events per 1,000 person-years following laparoscopic procedures and 0.8 events per 1,000 person-years following open procedures. Although these rates were lower than those observed among donors, they exceeded those expected in the general population. Additionally, higher rates were observed in the laparoscopic surgery group compared to the open surgery group. These analyses were descriptive and unadjusted for confounding but suggested a potential mechanistic link.

One hypothesis is that surgical manipulation of the renal pelvis and/or ureter may disrupt lymphatic or venous drainage to the scrotum, contributing to hydrocele formation. This proposed mechanism has prompted further investigation into whether similar postoperative scrotal complications occur following other urological procedures involving manipulation of the collecting system, such as pyeloplasty.

Primary Objective: To evaluate whether males who underwent laparoscopic pyeloplasty have a higher risk of a hospital admission for hydrocelectomy compared to males with similar indicators of baseline health selected from the general population.

*Study Setting and Data Sources*

This study will be conducted at ICES (ices.on.ca). ICES is an independent, non-profit research institute with legal authority under Ontario's health information privacy legislation to collect and analyze health care and demographic data without individual consent for the purposes of health system evaluation and improvement. Data use for this project is authorized under Section 45 of Ontario's Personal Health Information Protection Act (PHIPA), which does not require Research Ethics Board approval.

Data from multiple linked databases will be used to identify the cohort, establish baseline characteristics, and define outcomes. These databases include Ontario's Registered Persons Database (RPDB), the Ontario Health Insurance Plan (OHIP), and Canadian Institute for Health Information's (CIHI) Discharge Abstract Database (DAD), National Ambulatory Care Reporting System (NACRS), and Same Day Surgery (SDS).

Given the nature of the data sources, minimal missingness is expected across the study variables. This retrospective cohort study will rely entirely on existing administrative health data available at ICES. To promote research transparency and reproducibility, this study protocol will be registered on ClinicalTrials.gov, including the design and statistical analysis plan, prior to initiating any outcome analyses.

*Study Population*

Those who underwent pyeloplasty will be identified using hospitalization records and admissions in CIHI-DAD and SDS from 1992 to 2024. Only the first pyeloplasty that occurs will be examined. Three cohorts will be constructed: laparoscopic pyeloplasty, open pyeloplasty, and non-pyeloplasty controls.

*Baseline Characteristics and Matching*

Baseline variables will be assessed at the index date, defined as the date of the first pyeloplasty surgery. For general population comparators who did not undergo pyeloplasty, an index date will be randomly assigned based on the distribution of index dates in the pyeloplasty group. Baseline characteristics will be summarized using descriptive statistics and standardized differences. To reduce confounding, 1:4 propensity score matching will be performed, pairing each pyeloplasty patient with up to four controls using greedy nearest-neighbour matching without replacement. Matching variables will include propensity score, age, and index date. Post-matching balance will be assessed using standardized mean differences.

*Outcomes*

The primary outcome is hospital admission and receipt of surgery for hydrocele excision (i.e., hydrocelectomy). To ensure accurate outcome ascertainment, evidence of both a hospital-based procedural code (CCI codes: 1QH87LA, 1QH87LB, 1QH52HA, 1QH52LA, 1QH80LA, 1QG52HA, 1QG52LA; CCP codes: 731, 730, 7391, 7339) and a surgeon fee-for-service code (OHIP fee codes: S611, S630) is required, with each recorded in separate healthcare databases within 30 days of one another. The date of hospital admission will be recorded as the outcome date. Observation time will be censored at death, emigration, or the maximum follow-up date (March 31, 2025). Secondary outcomes include receipt of a scrotal ultrasound and diagnosis of hydrocele.

*Statistical Analysis*

Three primary cohorts will be defined: (1) laparoscopic pyeloplasty, (2) open pyeloplasty, and (3) non-pyeloplasty controls. For all pyeloplasty patients, the index date will be the date of surgery. For controls, index dates will be assigned by bootstrapping from the distribution of pyeloplasty index dates. The primary analysis will compare laparoscopic pyeloplasty with matched non-pyeloplasty controls.

Incidence rates (per 1,000 person-years), rate differences, and hazard ratios (HRs) will be calculated using Cox proportional hazards models with robust variance to account for matching. If the proportional hazards assumption is violated, stratified log-rank tests will be used, and restricted mean survival times will be estimated at 20 years. Cumulative incidence will be estimated using Aalen-Johansen methods to account for the competing risk of death and reported at 1, 5, 10, 15, 20, and 25 years.

In subgroup analyses, we will stratify by age (<18, 18 to <70, 70+) and cohort entry year (1992 to 2002, 2003 to 2013, 2014 to 2024), with primary outcome analyses repeated within each subgroup.

*Additional Analyses*

In additional analyses, the primary analysis will be repeated comparing different cohorts. These additional comparisons include:

1. Laparoscopic pyeloplasty vs. open pyeloplasty (primary and secondary outcomes)
2. Open pyeloplasty vs. non-pyeloplasty controls (only primary outcome)

For comparisons of surgery types (e.g., laparoscopic vs. open), inverse probability of treatment weighting (IPTW) using propensity scores will be applied.

All estimates will be reported with 95% confidence intervals. Hierarchical testing will be applied, with significance testing stopping after the first non-significant result (α = 0.05 per test); all remaining estimates will be presented without p-values.

• Study Type: Observational
• Enrollment (Actual): 15000

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

• Sampling Method: Non-Probability Sample

Study Population

The laparoscopic pyeloplasty cohort will include all male Ontario residents who underwent laparoscopic pyeloplasty between July 1, 1992, and March 31, 2024. The open pyeloplasty cohort will include all male Ontario residents who underwent open pyeloplasty between July 1, 1992, and March 31, 2024, with the date of surgery serving as the index date. The non-pyeloplasty comparator group will be drawn from the general population of male Ontario residents. Controls will be assigned a random index date based on the distribution of surgery dates in the laparoscopic and open pyeloplasty cohorts (1992-2024). Each patient in the laparoscopic and open pyeloplasty cohorts will be matched to up to four non-pyeloplasty controls.

Description

*Laparoscopic Pyeloplasty Cohort*

Inclusion Criteria:

This cohort will include male individuals who underwent a laparoscopic pyeloplasty between July 1, 1992, and March 31, 2024. For patients who have undergone more than one pyeloplasty, only the first procedure will be considered.

Exclusion Criteria:

• Individuals with data record errors (e.g., missing or invalid age, sex, or date of birth), who are less than 0 years of age or greater than 105 years of age, with a death record on or before their cohort entry, or are non-Ontario residents or are OHIP ineligible on the index date (to restrict to permanent residents of the province).
• Anyone who had laparoscopic surgery to open surgery for pyeloplasty in the same index
• Previous scrotal or genital conditions or procedures (includes cancers, hydroceles, scrotal ultrasounds, etc.)

*Non-Pyeloplasty Control Cohort*

Inclusion Criteria:

The control cohort will consist of male individuals identified in the RPDB (the general Ontario population). Index dates will be randomly assigned by bootstrapping dates from the pyeloplasty group, such that each control is assigned an actual pyeloplasty index date randomly sampled with replacement from that group. Controls will be carefully screened to ensure that none are included in the pyeloplasty cohorts.

Exclusion Criteria:

• Individuals with data record errors (e.g., missing or invalid age, sex, or date of birth), who are less than 0 years of age or greater than 105 years of age, with a death record on or before their cohort entry, or are non-Ontario residents or are OHIP ineligible on the index date (to restrict to permanent residents of the province).
• Any evidence of previous pyeloplasty surgeries
• Previous scrotal or genital conditions or procedures (includes cancers, hydroceles, scrotal ultrasounds, etc.)

*Open Pyeloplasty Cohort*

Inclusion Criteria:

The open cohort will include male individuals who underwent an open pyeloplasty between July 1, 1992, and March 31, 2024. For patients who have undergone more than one pyeloplasty, only the first procedure will be considered.

Exclusion Criteria:

• Individuals with data record errors (e.g., missing or invalid age, sex, or date of birth), who are less than 0 years of age or greater than 105 years of age, with a death record on or before their cohort entry, or are non-Ontario residents or are OHIP ineligible on the index date (to restrict to permanent residents of the province).
• Anyone who had laparoscopic surgery to open surgery for pyeloplasty in the same index
• Previous scrotal or genital conditions or procedures (includes cancers, hydroceles, scrotal ultrasounds, etc.)

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Laparoscopic pyeloplasty; Ontario males who underwent laparoscopic pyeloplasty between July 1, 1992 and March 31, 2024. Hospital procedure code (CCI code: 1PE80DA, 1PE80DAFH, 1PE80DAXXE, 1PE76DA; CCP code: 6771, 6777) and a surgeon-fee-for-service code (OHIP fee code: S422 AND E792) within 30 days.	Procedure: Pyeloplasty; Underwent a pyeloplasty procedure from July 1, 1992, and March 31, 2024
Non-pyeloplasty controls; Males of the general Ontario population who did not undergo pyeloplasty surgery.
Open pyeloplasty; Include Ontario males who underwent open pyeloplasty between July 1, 1992 and March 31, 2024. Hospital procedure code (CCI code: 1PE80LA, 1PE80LAFH, 1PE80LAXXE, 1PE80LAXXF, 1PE80LAXXG, 1PE80PF, 1PE80PFFH, 1PE80PFXXE, 1PE80PFXXF, 1PE80PFXXG; CCP code: 6771, 6777) and a surgeon-fee-for-service code (OHIP fee code: S422 with NO evidence of E792) within 30 days.	Procedure: Pyeloplasty; Underwent a pyeloplasty procedure from July 1, 1992, and March 31, 2024

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hydrocelectomy	A hospital-based procedural code (CCI code: 1QH87LA, 1QH87LB, 1QH52HA, 1QH52LA, 1QH80LA, 1QG52HA, 1QG52LA; CCP code: 731, 730, 7391, 7339) and a surgeon-fee-for-service code (OHIP fee code: S611, S630) within 30 days.	Follow-up period (index date to outcome, emigration, or maximum follow-up date [March 31, 2025]).

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Hydrocele diagnosis	A hospital-based diagnosis code (ICD-9 code: 6030, 6031, 6038, 6039; ICD-10-CA code: N43, N430, N431, N432, N433, P835) and an OHIP claims diagnostic code (OHIP diagnostic code: 603) and a scrotal ultrasound within 6 months, including the date of the ultrasound (OHIP fee code: J183).	Follow-up period (index date to outcome, emigration, or maximum follow-up date [March 31, 2025]).
Scrotal ultrasound	OHIP fee code: J183	Follow-up period (index date to outcome, emigration, or maximum follow-up date [March 31, 2025]).

Collaborators and Investigators

• Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Publications and helpful links

General Publications

• Garg AX, McArthur E, Sontrop JM, Boudville N, Connaughton DM, Cuerden MS, Feldman LS, Lam NN, Lentine KL, Nguan C, Parikh CR, Segev DL, Sener A, Smith G, Wang C, Weir MA, Yohanna S, Young A, Naylor KL. Risk for Scrotal Surgery After Laparoscopic Donor Nephrectomy : A Population-Based Cohort Study. Ann Intern Med. 2026 Jan;179(1):23-31. doi: 10.7326/ANNALS-25-02257. Epub 2025 Nov 11.

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 1992
• Primary Completion (Actual): March 31, 2024
• Study Completion (Actual): March 31, 2025

Study Registration Dates

• First Submitted: March 16, 2026
• First Submitted That Met QC Criteria: March 16, 2026
• First Posted (Actual): March 19, 2026

Study Record Updates

• Last Update Posted (Actual): March 19, 2026
• Last Update Submitted That Met QC Criteria: March 16, 2026
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Keywords: hydrocele; pyeloplasty; hydrocelectomy
• Additional Relevant MeSH Terms: Urogenital Diseases; Genital Diseases; Endocrine System Diseases; Genital Diseases, Male; Male Urogenital Diseases; Gonadal Disorders; Testicular Diseases; Testicular Hydrocele
• Other Study ID Numbers: 2026 0906 626 001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: The dataset from this study is held securely in coded form at ICES. While legal data sharing agreements between ICES and data providers (e.g., healthcare organizations and government) prohibit ICES from making the dataset publicly available, access may be granted to those who meet pre-specified criteria for confidential access, available at www.ices.on.ca/DAS (email: das@ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely upon coding templates or macros that are unique to ICES and are therefore either inaccessible or may require modification.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No